Navigation Links
Align Technology Executives to Present at Upcoming Financial Conferences
Date:5/6/2009

SANTA CLARA, Calif., May 6 /PRNewswire-FirstCall/ -- Align Technology, Inc. (Nasdaq: ALGN) announced today that executives of Align Technology, are scheduled to speak at two upcoming financial conferences. Both presentations, as noted below, will be web cast live via the Investor Relations section of Align Technology's website at http://investor.aligntech.com. An archived replay will remain on the web site for approximately three months.

    Conference:   Bank of America 2009 Health Care Conference, New York,
                  New York
    Date:         Tuesday, May 12, 2009
    Presentation: 11:20 to 11:50 a.m. Eastern Time
    Speaker:      Kenneth Arola, Vice President Finance and CFO

    Conference:   Deutsche Bank 34th Annual Health Care Conference, Boston,
                  Massachusetts
    Date:         Tuesday, May 19, 2009
    Presentation: 7:30 to 7:55 a.m. Eastern Time
    Speakers:     Thomas M. Prescott, President and CEO, and Kenneth Arola,
                  Vice President Finance and CFO


About Align Technology, Inc.

Align Technology designs, manufactures and markets Invisalign, a proprietary method for treating malocclusion, or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. Because it does not rely on the use of metal or ceramic brackets and wires, Invisalign significantly reduces the aesthetic and other limitations associated with braces. Invisalign is appropriate for treating adults and teens. Align Technology was founded in March 1997 and received FDA clearance to market Invisalign in 1998. Today, the Invisalign product family includes Invisalign, Invisalign Teen, Invisalign Assist, Invi
'/>"/>

SOURCE Align Technology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Align Technology Announces First Quarter Fiscal 2009 Results
2. Non-invasive test accurately identifies gynecologic malignancies
3. Can EUS elastography help distinguish benign from malignant tissue?
4. Do patients at risk for B-cell malignancy need antiviral treatment?
5. Align Technology Announces ClearCorrects Filing of Notice of Voluntary Dismissal of Complaint
6. Quantum and IBM Align to Drive Medical Home Solution
7. ABAXIS Realigns North American Medical Sales and Marketing
8. Align Technology to Announce First Quarter Fiscal 2009 Results on April 23, 2009
9. NovaLign(TM) Orthopaedics, Inc. Announces its First 510(K) Clearance From the FDA for New Intramedullary Fixation System
10. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
11. Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... HealthDay Reporter SATURDAY, ... comparison, an experimental drug was more effective than standard ... patients. According to the study authors, the trial ... the new drug, dubbed LCZ696. In the ... enalapril (Vasotec), either died or were hospitalized due to ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 Liver ... the one vital organ that helps the body in barring ... as a store of energy. Liver also plays many important ... cholesterol, iron and glucose. , Many illnesses can affect ... just under the rib cage on the right side of ...
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... Dennis Thompson HealthDay ... An experimental Ebola drug previously given to two American aid ... deadly virus in laboratory tests, researchers report. The drug, ... even if they didn,t get the medication until five days ... of Ebola who were days or even hours away from ...
(Date:9/1/2014)... As well as having completed the Non ... counselor certification in Louisiana. , "I have ... program as well as the Counselor training program ... and professionally. I am not only dedicated to ... do so. As a Non Violent Crisis Intervention ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Narconon Louisiana Announces New Certifications For Staff 2
... ... offering them to the public. , ... Austin, Texas (PRWEB) June 9, 2009 -- An Olympus digital voice recorder ... consumers. Recorders.com, the leading supplier of Olympus digital voice recorders in the United States, ...
... 9 June 2009 - Researchers have been seeking ... impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) ... may contribute to the underlying neurobiology of this ... stimulate NMDA receptors administered large amounts of substances, ...
... DNA binding compound has proved surprisingly effective at binding to ... touched within two minutes. The DNA binding properties of the ... the University of Warwick by Professor Mike Hannon and Professor ... of Birmingham). However the strength of its antibiotic powers have ...
... June 9 BioMarin Pharmaceutical Inc. (Nasdaq: ... clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) ... expects to initiate the Phase 2 clinical study in ... (IRB) approval from the clinical trial sites. The ...
... Protein Widely Expressed on Tumors and Tumor Blood Vessel ... Morphotek(R), Inc., a subsidiary of Eisai Corporation of North ... (FDA) cleared its investigational new drug (IND) application to ... tumors. MORAb-004 targets endosialin, a protein expressed on cells ...
... Bruce Matter has joined healthcare IT software provider, ... growth and client satisfaction. Peminic, with offices in Princeton, ... solutions to over 400 acute care and other healthcare ... legal matters. , , Teaming with hospitals, health ...
Cached Medicine News:Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 2Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 3Health News:Animal model for schizophrenia identifies a novel approach for treating cognitive impairments 2Health News:New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 3Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 4Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare IT Company, Peminic, Inc. as Company Growth in the Areas of Patient Safety, Risk Management, and Patient Satisfaction Accelerates 2
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... YORK, Dec. 8, 2010 Reportlinker.com announces that ... its catalogue: Global Generic Pharmaceuticals ... The Global Generic Pharmaceuticals Industry Report ... evaluation of the Global Generic Pharmaceuticals Industry Report. ...
... Ill., Dec. 8, 2010 Life Spine announced today ... the OCTAVE Posterior Fusion System, which is intended for ... achieving fusion in conjunction with bone graft. The U.S. ... to the OCTAVE System last month. ...
Cached Medicine Technology:Reportlinker Adds Global Generic Pharmaceuticals Industry Report 2Reportlinker Adds Global Generic Pharmaceuticals Industry Report 3Reportlinker Adds Global Generic Pharmaceuticals Industry Report 4Reportlinker Adds Global Generic Pharmaceuticals Industry Report 5Reportlinker Adds Global Generic Pharmaceuticals Industry Report 6Reportlinker Adds Global Generic Pharmaceuticals Industry Report 7
... Autoref / Ker Accuref K ... inch LCD color monitor. 3 ... range. 2.3 mm Minimum pupil ... light adjuster. Auto start function. ...
... is the child-friendly, portable autorefractor that ... adults. It can perform objective refraction ... cm) away even through glasses and ... and sounds engage the patient throughout ...
Neomycin and Polymyxin B sulfates and Dexamethasone ophthalmic ointment is a multiple dose anti-infective steroid combination in sterile ointment form for topical applications....
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
Medicine Products: